October 11, 2016
A California federal judge has tossed a proposed class action targeting pharmaceutical maker Celladon Corp. and two executives for allegedly misleading shareholders about the success of a heart therapy drug prior to suspending development, saying the investor heading the suit hadn't shown any false statements.